Roche Holding AG (RHHVF)
289.09
-5.79
(-1.96%)
USD |
OTCM |
Nov 14, 16:00
Roche Enterprise Value: 263.23B for Nov. 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 14, 2024 | 263.23B |
| November 13, 2024 | 267.84B |
| November 12, 2024 | 271.41B |
| November 11, 2024 | 271.99B |
| November 08, 2024 | 271.79B |
| November 07, 2024 | 274.17B |
| November 06, 2024 | 273.67B |
| November 05, 2024 | 278.53B |
| November 04, 2024 | 281.88B |
| November 01, 2024 | 281.95B |
| October 31, 2024 | 278.37B |
| October 30, 2024 | 281.72B |
| October 29, 2024 | 284.38B |
| October 28, 2024 | 286.27B |
| October 25, 2024 | 288.53B |
| October 24, 2024 | 288.65B |
| October 23, 2024 | 288.65B |
| October 22, 2024 | 282.87B |
| October 21, 2024 | 281.38B |
| October 18, 2024 | 281.98B |
| October 17, 2024 | 281.94B |
| October 16, 2024 | 277.98B |
| October 15, 2024 | 283.87B |
| October 14, 2024 | 281.88B |
| October 11, 2024 | 281.13B |
| Date | Value |
|---|---|
| October 10, 2024 | 277.79B |
| October 09, 2024 | 281.19B |
| October 08, 2024 | 276.81B |
| October 07, 2024 | 274.49B |
| October 04, 2024 | 272.15B |
| October 03, 2024 | 277.16B |
| October 02, 2024 | 283.35B |
| October 01, 2024 | 281.84B |
| September 30, 2024 | 286.49B |
| September 27, 2024 | 289.45B |
| September 26, 2024 | 288.65B |
| September 25, 2024 | 285.60B |
| September 24, 2024 | 288.20B |
| September 23, 2024 | 282.49B |
| September 20, 2024 | 286.45B |
| September 19, 2024 | 285.98B |
| September 18, 2024 | 283.77B |
| September 17, 2024 | 285.68B |
| September 16, 2024 | 282.15B |
| September 13, 2024 | 278.62B |
| September 12, 2024 | 276.70B |
| September 11, 2024 | 284.84B |
| September 10, 2024 | 283.66B |
| September 09, 2024 | 281.42B |
| September 06, 2024 | 289.81B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
212.94B
Minimum
May 06 2024
368.05B
Maximum
Dec 29 2021
288.81B
Average
288.09B
Median
Enterprise Value Benchmarks
| AC Immune SA | 163.56M |
| CRISPR Therapeutics AG | 2.063B |
| Addex Therapeutics Ltd | 4.547M |
| NLS Pharmaceutics Ltd | 13.90M |
| Molecular Partners AG | 22.68M |
Enterprise Value Related Metrics
| Earnings Yield | 5.11% |
| Operating Earnings Yield | 7.06% |
| Normalized Earnings Yield | 5.299 |